

Spravato[®]
(esketamine) 
28 mg nasal spray 

For adults:

If you struggle with
treatment-resistant
depression, there's
**a different choice to
turn to.**

What is SPRAVATO[®]?

SPRAVATO[®] is a prescription medicine,
used along with an antidepressant
taken by mouth to treat:

- Adults with treatment-resistant depression (TRD)

SPRAVATO[®] is not for use as a medicine to
prevent or relieve pain (anesthetic). It is not
known if SPRAVATO[®] is safe or effective as an
anesthetic medicine.

It is not known if SPRAVATO[®] is safe and effective
for use in preventing suicide or in reducing suicidal
thoughts or actions. SPRAVATO[®] is not for use in
place of hospitalization if your healthcare provider
determines that hospitalization is needed, even if
improvement is experienced after the first dose of
SPRAVATO[®].

It is not known if SPRAVATO[®] is safe and effective
in children.

**Please see Important Safety Information in this
brochure. Please see full Prescribing Information,
including **Boxed WARNINGS**, and Medication Guide
for SPRAVATO[®] and discuss any questions you may
have with your healthcare provider.**

What is the most important information I should know about SPRAVATO[®]?

SPRAVATO[®] can cause serious side effects, including:

- **Sedation and dissociation.** SPRAVATO[®] may cause sleepiness (sedation), fainting, dizziness, spinning sensation, anxiety, or feeling disconnected from yourself, your thoughts, feelings, space and time (dissociation).
 - Tell your healthcare provider right away if you feel like you cannot stay awake or if you feel like you are going to pass out.
 - Your healthcare provider must monitor you for serious side effects for at least 2 hours after taking SPRAVATO[®]. Your healthcare provider will decide when you are ready to leave the healthcare setting.
- **Abuse and misuse.** There is a risk for abuse and physical and psychological dependence with SPRAVATO[®] treatment. Your healthcare provider should check you for signs of abuse and dependence before and during treatment with SPRAVATO[®].
 - Tell your healthcare provider if you have ever abused or been dependent on alcohol, prescription medicines, or street drugs.
 - Your healthcare provider can tell you more about the differences between physical and psychological dependence and drug addiction.
- **SPRAVATO[®] Risk Evaluation and Mitigation Strategy (REMS).** Because of the risks for sedation, dissociation, and abuse and misuse, SPRAVATO[®] is only available through a restricted program called the SPRAVATO[®] Risk Evaluation and Mitigation Strategy (REMS) Program. SPRAVATO[®] can only be administered at healthcare settings certified in the SPRAVATO[®] REMS Program. Patients treated in outpatient healthcare settings (e.g., medical offices and clinics) must be enrolled in the program.

Please see additional Important Safety Information in this brochure. Please see full Prescribing Information, including Boxed WARNINGS, and Medication Guide for SPRAVATO[®] and discuss any questions you may have with your healthcare provider.

- **Increased risk of suicidal thoughts and actions.** Antidepressant medicines may increase suicidal thoughts and actions in some people 24 years of age and younger, **especially within the first few months of treatment or when the dose is changed. SPRAVATO[®] is not for use in children**
 - Depression and other serious mental illnesses are the most important causes of suicidal thoughts and actions. Some people may have a higher risk of having suicidal thoughts or actions. These include people who have (or have a family history of) depression or a history of suicidal thoughts or actions.
- **How can I watch for and try to prevent suicidal thoughts and actions in myself or a family member?**
 - Pay close attention to any changes, especially sudden changes, in mood, behavior, thoughts, or feelings, or if you develop suicidal thoughts or actions.
 - Tell your healthcare provider right away if you have any new or sudden changes in mood, behavior, thoughts, or feelings.
 - Keep all follow-up visits with your healthcare provider as scheduled. Call your healthcare provider between visits as needed, especially if you have concerns about symptoms.
- **Tell your healthcare provider right away if you or your family member have any of the following symptoms, especially if they are new, worse, or worry you:**
 - suicide attempts
 - worsening depression
 - thoughts about suicide or dying
 - other unusual changes in behavior or mood

Please see additional Important Safety Information in this brochure. Please see full Prescribing Information, including Boxed WARNINGS, and Medication Guide for SPRAVATO[®] and discuss any questions you may have with your healthcare provider.

Discover SPRAVATO®.

It's the first FDA-approved nasal spray specifically for adults with treatment-resistant depression.

If you've tried two or more antidepressants* and are still struggling with depressive symptoms, talk to your healthcare provider to see if you may have treatment-resistant depression.

*Of adequate dose and duration during your current episode.

Ask your healthcare provider if SPRAVATO® may be right for you.

SPRAVATO® is not for use as a medicine to prevent or relieve pain (anesthetic). It is not known if SPRAVATO® is safe or effective as an anesthetic medicine.

It is not known if SPRAVATO® is safe and effective for use in preventing suicide or in reducing suicidal thoughts or actions. SPRAVATO® is not for use in place of hospitalization if your healthcare provider determines that hospitalization is needed, even if improvement is experienced after the first dose of SPRAVATO®.

It is not known if SPRAVATO® is safe and effective in children.



Spravato®
(esketamine) (III) 
28 mg nasal spray

Please see Important Safety Information in this brochure. Please see full Prescribing Information, including Boxed WARNINGS, and Medication Guide for SPRAVATO® and discuss any questions you may have with your healthcare provider.



SPRAVATO® works differently than other medications for treatment-resistant depression.

Today's most commonly used oral antidepressants are thought to treat depression by increasing levels of neurotransmitters (serotonin, norepinephrine and dopamine) in areas of the brain that affect mood.

SPRAVATO® targets the N-methyl-D-aspartate (NMDA) receptor and is believed to work differently than currently available oral antidepressants. The exact way that SPRAVATO® works is unknown. SPRAVATO® is taken with an oral antidepressant.



Visit [SPRAVATO.com](https://www.spravato.com)

Please see Important Safety Information in this brochure. Please see full Prescribing Information, including Boxed WARNINGS, and Medication Guide for SPRAVATO® and discuss any questions you may have with your healthcare provider.

SPRAVATO® was proven effective for adults with treatment-resistant depression when taken with an oral antidepressant.

In a short-term clinical study of adults with treatment-resistant depression,* those who took SPRAVATO® and an oral antidepressant experienced a greater reduction of depression symptoms at four weeks† (compared to those who received a placebo and an oral antidepressant).

In a long-term study after 16 weeks of therapy, patients who stayed on SPRAVATO®‡ were less likely to experience a return of depressive symptoms than those who stopped therapy.

Ask your healthcare provider if SPRAVATO® is right for you.

*Adults with major depressive disorder who have not responded sufficiently to at least two different antidepressants of adequate dose and duration in the current episode.

†Defined as an improvement of at least 50% based on an overall score on a standardized rating scale.

‡Along with an oral antidepressant.



Visit [SPRAVATO.com](https://www.spravato.com)

Please see Important Safety Information in this brochure. Please see full Prescribing Information, including Boxed WARNINGS, and Medication Guide for SPRAVATO® and discuss any questions you may have with your healthcare provider.

SPRAVATO® Side Effects

Serious side effects of SPRAVATO® include feeling sleepy (sedation), dissociation, abuse and misuse, increased risk of suicidal thoughts and behavior, increased blood pressure, problems with thinking clearly, and bladder problems.

For additional information on these serious side effects, please see **Important Safety Information** in this brochure.

Most Common Side Effects

- Feeling disconnected from yourself, your thoughts, feelings and things around you (dissociation)
- Dizziness
- Nausea
- Feeling sleepy (sedation)
- Spinning sensation
- Decreased feeling of sensitivity (numbness)
- Feeling anxious
- Lack of energy
- Increased blood pressure
- Vomiting
- Feeling drunk
- Feeling very happy or excited

If these common side effects occur, they usually happen right after taking SPRAVATO® and go away the same day.

These are not all the possible side effects of SPRAVATO®. Please see the SPRAVATO® **Medication Guide** for the complete safety information.



Visit [SPRAVATO.com](https://www.spravato.com)

Please see Important Safety Information in this brochure. Please see full Prescribing Information, including Boxed WARNINGS, and Medication Guide for SPRAVATO® and discuss any questions you may have with your healthcare provider.

“When you’re
depressed, you forget
about the little things
you used to enjoy. I’m
catching up on all that
now.”

Robin P., 59, Berkeley, CA
Real patient with
treatment-resistant depression

Individual results may vary. Testimonial shared in 2018.
Robin is a real patient with treatment-resistant depression
and has been compensated for her time by Janssen
Pharmaceuticals, Inc.

**Please see Important Safety Information in this
brochure. Please see full Prescribing Information,
including **Boxed WARNINGS**, and Medication Guide
for SPRAVATO[®] and discuss any questions you may
have with your healthcare provider.**



What to Expect

SPRAVATO® (esketamine) CIII nasal spray can only be administered under the supervision of a healthcare provider at a treatment center that is certified in the SPRAVATO® Risk Evaluation and Mitigation Strategy (REMS) Program. This could be a different location than your doctor's office.

As part of the REMS, a healthcare provider will discuss the risks of sedation, dissociation, and abuse and misuse with you before starting SPRAVATO®. You and a healthcare provider must complete a Patient Enrollment Form for you to receive SPRAVATO® in a certified treatment center. For more information about the REMS, visit SPRAVATOREMS.com/patients




You and your healthcare provider can locate certified SPRAVATO® treatment centers near you by entering your ZIP code at SPRAVATO.com/find-a-center

Spravato®
(esketamine) CIII
28 mg nasal spray

Visit SPRAVATO.com

Please see Important Safety Information in this brochure. Please see full Prescribing Information, including Boxed WARNINGS, and Medication Guide for SPRAVATO® and discuss any questions you may have with your healthcare provider.



Discuss with Your Healthcare Provider Before Taking SPRAVATO®:

SPRAVATO® is not for everyone. Talk to your healthcare provider about your full medical history, including if you:

- have a history of abusing or being dependent on prescription or street drugs
- have a problem with alcohol
- are pregnant or planning to become pregnant
- are breastfeeding or planning to breastfeed
- take prescription or over-the-counter medicines
- take vitamins or herbal supplements

After starting SPRAVATO® treatment, make sure your healthcare provider has access to your medical information from the treatment center so that they are aware of how your treatment plan is progressing. Please read the **Medication Guide** for additional topics for discussion with your healthcare provider.



Visit [SPRAVATO.com](https://www.spravato.com)

Please see Important Safety Information in this brochure. Please see full Prescribing Information, including Boxed WARNINGS, and Medication Guide for SPRAVATO® and discuss any questions you may have with your healthcare provider.



Your First Treatment Center Visit

Your healthcare provider will continue to be involved with your care during SPRAVATO® treatment and will be available to answer questions or address concerns as you undergo treatment. Your first visit to the certified SPRAVATO® treatment center will be a consultation. The treatment center will:

- receive your medical information from your healthcare provider
- conduct its own assessment to determine if SPRAVATO® may be right for you
- verify your insurance information as part of the eligibility confirmation

If SPRAVATO® is recommended, the treatment center will build a treatment plan with you and enroll you in the SPRAVATO® REMS Program.



Remember: Make sure to follow up with your healthcare provider after your treatment plan is built.

Spravato®
(esketamine) 
28 mg nasal spray 

Visit [SPRAVATO.com](https://www.spravato.com)

Please see Important Safety Information in this brochure. Please see full Prescribing Information, including **Boxed WARNINGS, and Medication Guide for SPRAVATO® and discuss any questions you may have with your healthcare provider.**



Preparing for Treatment



You may start treatment as soon as your second visit to the SPRAVATO® treatment center.

Plan for rides to and from the treatment center. You won't be able to drive, operate machinery, or do anything where you need to be completely alert until the day after a treatment session, following a restful sleep.



Bring a form of entertainment, like a book or playlist, for the session. A healthcare provider at the treatment center will monitor you for at least two hours after treatment.



Avoid eating two hours before, and drinking liquids 30 minutes before, the treatment session. Some patients taking SPRAVATO® may experience nausea or vomiting.



If you take a nasal corticosteroid or nasal decongestant medicine, take these medicines at least one hour before taking SPRAVATO®.

Spravato®
(esketamine) 
28 mg nasal spray 

Visit [SPRAVATO.com](https://www.spravato.com)

Please see Important Safety Information in this brochure. Please see full Prescribing Information, including Boxed WARNINGS, and Medication Guide for SPRAVATO® and discuss any questions you may have with your healthcare provider.

“I no longer start off each day sad and about to cry. With SPRAVATO[®], I’m starting off at a place like neutral, which is, like, the best.”

Nicole P., 23, St. Peters, MO
Real patient with
treatment-resistant depression

Individual results may vary. Testimonial shared in 2018. Nicole is a real patient with treatment-resistant depression and has been compensated for her time by Janssen Pharmaceuticals, Inc.

Please see Important Safety Information in this brochure. Please see full Prescribing Information, including **Boxed WARNINGS, and Medication Guide for SPRAVATO[®] and discuss any questions you may have with your healthcare provider.**



Patient Support for SPRAVATO®

Once you and your healthcare provider have decided that SPRAVATO® is right for you, Janssen CarePath will help you find the resources you may need to get started and stay on track.

Paying for SPRAVATO®

Janssen CarePath can explain your potential out-of-pocket costs and identify cost support options that may help with managing your out-of-pocket costs—whether you have commercial or private health insurance, government coverage such as Medicare or Medicaid, or have no insurance coverage.

 Medical Claims Payer ID: 56155 GROUP: 00003636 Member:	 Pharmacy Claims BIN: 610020 GROUP: 99994002 Member:
<small>Physicians: For medical claims, patient may direct payment to you or elect to receive a mailed rebate check. Call 855-872-1776 to understand payment selection made by patient. Please read the accompanying full Prescribing Information, including Boxed WARNINGS and Medication Guide for SPRAVATO®, and discuss any questions you have with your doctor. PROGRAM REQUIREMENTS APPLY.</small>	

For commercially insured patients – see next page

Getting Started

Janssen CarePath can review your health plan benefits and insurance coverage for SPRAVATO® and offer treatment education resources.

Staying on Track

Janssen CarePath offers additional support to help you stay on track with your SPRAVATO® treatment prescribed by your healthcare provider.

Call a Janssen CarePath Care Coordinator at

877-CarePath (877-227-3728), Monday–Friday, 8:00 AM to 8:00 PM ET. Multilingual phone support is available.

Create a Janssen CarePath Account at [MyJanssenCarePath.com](https://www.MyJanssenCarePath.com) where you can: check your insurance coverage for SPRAVATO®; if eligible, enroll in the Janssen CarePath Savings Program and manage program benefits; and sign up for treatment support.

Visit [JanssenCarePath.com/Spravato](https://www.JanssenCarePath.com/Spravato).

Please see Important Safety Information in this brochure. Please see full Prescribing Information, including Boxed WARNINGS, and Medication Guide for SPRAVATO® and discuss any questions you may have with your healthcare provider.



Paying for SPRAVATO®

At Janssen, we don't want cost to get in the way of treatment you need. We can help you explore options to lower your out-of-pocket cost for SPRAVATO®. No matter what type of coverage you have – or even if you don't have coverage – Janssen CarePath can help explain your medication insurance coverage and potential out-of-pocket costs and help find programs that may help you pay for SPRAVATO®.

If you have commercial or private health insurance and need help paying for SPRAVATO®, the Janssen CarePath Savings Program may be able to help. Eligible commercially-insured patients pay **\$10 per treatment** for SPRAVATO® medication costs, with a \$7,150 maximum program benefit per calendar year. *Treatment* may include up to three devices administered on the same day. Program limits apply. Depending on how your insurance covers SPRAVATO®, there is a program benefit limit of list price of medication and a quantity limit of three devices per day or 23 devices in a 24-day period. There is a quantity limit of 24 devices in a 24-day period for one use per lifetime. Not valid for patients using Medicare, Medicaid, or other government-funded programs to pay for their medications. Terms expire at the end of each calendar year and may change. Program does not cover the cost to give you your treatment. See full eligibility requirements at [Spravato.JanssenCarePathSavings.com](https://www.spravato.janssencarepathsavings.com).

Enroll in the Savings Program to get a card for use at your healthcare provider's office or pharmacy.

[Create an account at MyJanssenCarePath.com.](https://www.myjanssencarepath.com)

[Express Enrollment for the Savings Program only at MyJanssenCarePath.com/express.](https://www.myjanssencarepath.com/express)

If you don't have commercial or private health insurance, Janssen CarePath can provide information about other resources that may help with your out-of-pocket medication costs. You may also find help from the programs and resources found on [JanssenCarePath.com](https://www.janssencarepath.com).

If you have any questions, please call a Janssen CarePath Care Coordinator at **877-CarePath (877-227-3728)**, Monday–Friday, 8:00 AM to 8:00 PM ET. Multilingual phone support is available.

[Visit JanssenCarePath.com/Spravato.](https://www.janssencarepath.com/spravato)

Please see Important Safety Information in this brochure. Please see full Prescribing Information, including Boxed WARNINGS, and Medication Guide for SPRAVATO® and discuss any questions you may have with your healthcare provider.

IMPORTANT SAFETY INFORMATION

Spravato[®]
(esketamine) 
28 mg nasal spray 

Do not take SPRAVATO[®] if you:

- have blood vessel (aneurysmal vascular) disease (including in the brain, chest, abdominal aorta, arms and legs)
- have an abnormal connection between your veins and arteries (arteriovenous malformation)
- have a history of bleeding in the brain
- are allergic to esketamine, ketamine, or any of the other ingredients in SPRAVATO[®].

If you are not sure if you have any of the above conditions, talk to your healthcare provider before taking SPRAVATO[®].

Before you take SPRAVATO[®], tell your healthcare provider about all of your medical conditions, including if you:

- have heart or brain problems, including:
 - high blood pressure (hypertension)
 - slow or fast heartbeats that cause shortness of breath, chest pain, lightheadedness, or fainting
 - history of heart attack
 - history of stroke
 - heart valve disease or heart failure
 - history of brain injury or any condition where there is increased pressure in the brain
- have liver problems
- have ever had a condition called “psychosis” (see, feel, or hear things that are not there, or believe in things that are not true).
- are pregnant or plan to become pregnant. SPRAVATO[®] may harm your baby. You should not take SPRAVATO[®] if you are pregnant.
 - Tell your healthcare provider right away if you become pregnant during treatment with SPRAVATO[®].
 - If you are able to become pregnant, talk to your healthcare provider about methods to prevent pregnancy during treatment with SPRAVATO[®].

Please see additional Important Safety Information in this brochure. Please see full Prescribing Information, including Boxed WARNINGS, and Medication Guide for SPRAVATO[®] and discuss any questions you may have with your healthcare provider.

IMPORTANT SAFETY INFORMATION (CONTINUED)

Spravato[®]
(esketamine) 
28 mg nasal spray 

- There is a pregnancy registry for women who are exposed to SPRAVATO[®] during pregnancy. The purpose of the registry is to collect information about the health of women exposed to SPRAVATO[®] and their baby. If you become pregnant during treatment with SPRAVATO[®], talk to your healthcare provider about registering with the National Pregnancy Registry for Antidepressants at 1-844-405-6185 or online at <https://womensmentalhealth.org/clinical-and-research-programs/pregnancyregistry/antidepressants/>.
- are breastfeeding or plan to breastfeed. You should not breastfeed during treatment with SPRAVATO[®].

Tell your healthcare provider about all the medicines that you take, including prescription and over-the-counter medicines, vitamins and herbal supplements. Taking SPRAVATO[®] with certain medicine may cause side effects.

Especially tell your healthcare provider if you take central nervous system (CNS) depressants, psychostimulants, or monoamine oxidase inhibitors (MAOIs) medicines. Keep a list of them to show to your healthcare provider and pharmacist when you get a new medicine.

How will I take SPRAVATO[®]?

- You will take SPRAVATO[®] nasal spray yourself, under the supervision of a healthcare provider in a healthcare setting. Your healthcare provider will show you how to use the SPRAVATO[®] nasal spray device.
- Your healthcare provider will tell you how much SPRAVATO[®] you will take and when you will take it.
- Follow your SPRAVATO[®] treatment schedule exactly as your healthcare provider tells you to.
- During and after each use of the SPRAVATO[®] nasal spray device, you will be checked by a healthcare provider who will decide when you are ready to leave the healthcare setting.
- You will need to plan for a caregiver or family member to drive you home after taking SPRAVATO[®].

Please see additional Important Safety Information in this brochure. Please see full Prescribing Information, including Boxed WARNINGS, and Medication Guide for SPRAVATO[®] and discuss any questions you may have with your healthcare provider.

IMPORTANT SAFETY INFORMATION (CONTINUED)

Spravato[®]
(esketamine) 
28 mg nasal spray 

- If you miss a SPRAVATO[®] treatment, your healthcare provider may change your dose and treatment schedule.
- Some people taking SPRAVATO[®] get nausea and vomiting. You should not eat for at least 2 hours before taking SPRAVATO[®] and not drink liquids at least 30 minutes before taking SPRAVATO[®].
- If you take a nasal corticosteroid or nasal decongestant medicine take these medicines at least 1 hour before taking SPRAVATO[®].

What should I avoid while taking SPRAVATO[®]?

Do not drive, operate machinery, or do anything where you need to be completely alert after taking SPRAVATO[®]. **Do not** take part in these activities until the next day following a restful sleep. See **“What is the most important information I should know about SPRAVATO[®]?”**

What are the possible side effects of SPRAVATO[®]?

SPRAVATO[®] may cause serious side effects including:

- See **“What is the most important information I should know about SPRAVATO[®]?”**
- **Increased blood pressure.** SPRAVATO[®] can cause a temporary increase in your blood pressure that may last for about 4 hours after taking a dose. Your healthcare provider will check your blood pressure before taking SPRAVATO[®] and for at least 2 hours after you take SPRAVATO[®]. Tell your healthcare provider right away if you get chest pain, shortness of breath, sudden severe headache, change in vision, or seizures after taking SPRAVATO[®].
- **Problems with thinking clearly.** Tell your healthcare provider if you have problems thinking or remembering.
- **Bladder problems.** Tell your healthcare provider if you develop trouble urinating, such as a frequent or urgent need to urinate, pain when urinating, or urinating frequently at night.

Please see additional Important Safety Information in this brochure. Please see full Prescribing Information, including Boxed WARNINGS, and Medication Guide for SPRAVATO[®] and discuss any questions you may have with your healthcare provider.

**IMPORTANT SAFETY
INFORMATION (CONTINUED)**



The most common side effects of SPRAVATO® when used along with an antidepressant taken by mouth include:

- feeling disconnected from yourself, your thoughts, feelings and things around you
- decreased feeling of sensitivity (numbness)
- dizziness
- feeling anxious
- nausea
- lack of energy
- feeling sleepy
- increased blood pressure
- spinning sensation
- vomiting
- feeling drunk
- feeling very happy or excited

If these common side effects occur, they usually happen right after taking SPRAVATO® and go away the same day.

These are not all the possible side effects of SPRAVATO®.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Please see full Prescribing Information, including Boxed WARNINGS, and Medication Guide for SPRAVATO® and discuss any questions you may have with your healthcare provider.

cp-79822v3

© Janssen Pharmaceuticals, Inc. 2021 08/21
cp-179457v2

Please see additional Important Safety Information in this brochure. Please see full Prescribing Information, including Boxed WARNINGS, and Medication Guide for SPRAVATO® and discuss any questions you may have with your healthcare provider.

Ask your healthcare provider
if SPRAVATO® should be part
of your treatment plan.

Spravato®
(esketamine) 
28 mg nasal spray

Visit [SPRAVATO.com](https://www.spravato.com)

Please see Important Safety Information in this brochure. Please see full Prescribing Information, including **Boxed WARNINGS, and Medication Guide for SPRAVATO® and discuss any questions you may have with your healthcare provider.**